Hemostemix receives $330,000 lead order for placement

Executive Summary

• Hemostemix Inc. received a lead order of $330,000 for a non‑brokered private placement with total capacity up to $700,000.
• Units are priced at C$0.11 and consist of one common share plus one warrant exercisable at C$0.15 per share for two years, with an acceleration feature tied to the market price.
• Proceeds will be used for general working capital, primarily to fund ongoing operational expenses and marketing/sales of the VesCell therapy platform.

Key Details

• Lead Order Amount: C$330,000 (up to a total of C$700,000).
• Unit Pricing: C$0.11 per unit; each unit = 1 common share + 1 warrant.
• Warrant Terms: Exercise price C$0.15 per share; term of two years from closing date.
• Accelerator Clause: If, after four months + one day, the closing sales price exceeds a weighted‑average of C$0.185 over any 10‑day period, the company may accelerate warrant expiry to 30 days after a press‑release notice.
• Related‑Party Participation: A director is participating; transaction qualifies as a related‑party under MI 61‑101 but is exempt from formal valuation and minority approval requirements.
• Use of Proceeds: General working capital, including marketing and sales activities for the VesCell (ACP‑01) autologous stem cell therapy.

Notable Quotes

(No direct quotes were provided in the release.)